Valuation: Armata Pharmaceuticals, Inc.

Market Cap 192M 169M 157M 144M 270M 18.56B 275M 1.87B 730M 9.05B 719M 704M 31.4B P/E 2026 *
-1.37x
P/E 2027 * -3.9x
Enterprise Value 192M 169M 157M 144M 270M 18.56B 275M 1.87B 730M 9.05B 719M 704M 31.4B EV / Sales 2026 *
87.1x
EV / Sales 2027 * 69.7x
Free-Float
31.49%
Yield 2026 *
-
Yield 2027 * -
1 day-0.38%
1 week+38.83%
Current month-19.44%
1 month-25.53%
3 months-61.42%
6 months-13.00%
Current year-16.88%
1 week 4.58
Extreme 4.58
5.5
1 month 3.48
Extreme 3.48
7.63
Current year 3.48
Extreme 3.48
14.98
1 year 2.35
Extreme 2.35
16.34
3 years 0.9
Extreme 0.8981
16.34
5 years 0.83
Extreme 0.8311
16.34
10 years 0.83
Extreme 0.8311
16.34
Manager TitleAgeSince
Chief Executive Officer 70 11/07/2023
Director of Finance/CFO 42 16/08/2024
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member 62 09/05/2019
Director/Board Member 66 12/02/2020
Director/Board Member 51 12/02/2020
Date Insider Type Main position Quantity % Market Cap.
10/07/26 Tax

Chief Executive Officer

-14,041 0.0382%
24/04/26 Free

Director

51,280 0.1400%
14/03/26 Tax

Chief Executive Officer

4,919 0.0135%
Change 5-day change 1-year change 3-year change Capi.($)
-0.38%+38.83%+117.50%+353.91% 192M
+1.23%+0.35%+51.62%+87.98% 55.92B
+3.66%+9.89%+67.29%+72.56% 56.67B
+0.25%+0.55%-19.67%-15.22% 23.28B
+0.72%-0.05%+3.84%+409.54% 23.28B
-0.36%+5.73%+30.99%-3.58% 20.54B
-0.66%+1.20%+25.89%-29.79% 17.78B
-1.44%+5.67%+32.54%+544.11% 15.9B
-2.54%-8.73%+164.11%+289.45% 14.64B
+1.22%-0.05%+22.58%+182.63% 13.99B
Average +0.17%+5.02%+49.67%+189.16% 24.22B
Weighted average by Cap. +0.98%+3.20%+44.12%+136.75%

Financials

2026 *2027 *
Net sales 2.2M 1.93M 1.8M 1.65M 3.1M 213M 3.16M 21.49M 8.38M 104M 8.26M 8.08M 361M 2.75M 2.42M 2.25M 2.07M 3.88M 266M 3.94M 26.87M 10.48M 130M 10.32M 10.1M 451M
Net income -172M -151M -140M -129M -242M -16.65B -247M -1.68B -655M -8.12B -645M -631M -28.17B -66.35M -58.35M -54.21M -49.86M -93.5M -6.43B -95.18M -648M -253M -3.13B -249M -244M -10.87B
Net Debt - -
Logo Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. It is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. It is advancing two lead candidates, such as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections. Its lead phage candidate, inhaled AP-PA02, focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection. Its AP-PA03 is focused on the treatment of acute ventilator-associated pneumonia.
Employees
61
Date Price Change Volume
23/07/26 $5.220 -0.38% 102,209
22/07/26 $5.240 +1.55% 127,648
21/07/26 $5.160 +1.98% 270,136
20/07/26 $5.060 +12.20% 538,228
17/07/26 $4.510 +19.95% 271,343
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
5.220USD
Average target price
17.50USD
Spread / Average Target
+235.25%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARMP Stock